ArticleImmunity, inflammation and disease2020
Low dose IL-2 suppress osteoclastogenesis in collagen-induced arthritis via JNK dependent pathway.
Article in Immunity, inflammation and disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 10 citations in OpenAlex.
- REJENERAInflammopharmacology · 2026Article
- Rheumatoid Arthritis and Osteoporosis as Prototypes of Immunosenescence in Osteoimmunology: Molecular Pathways of Inflammaging and Targeted Therapies.International journal of molecular sciences · 2025Review
- The Role of Cytokines in Orthodontic Tooth Movement.International journal of molecular sciences · 2025Review
- Unraveling the genetic basis of the causal association between inflammatory cytokines and osteonecrosis.Frontiers in endocrinology · 2024Article
- Osteoimmunology: A Link between Gastrointestinal Diseases and Skeletal Health in Chickens.Animals : an open access journal from MDPI · 2023Review
- Corrigendum.Immunity, inflammation and disease · 2022Article
- Effects of a low-dose IL-2 treatment in HLA-B27 transgenic rat model of spondyloarthritis.Arthritis research & therapy · 2021Article
- Ultra-Low Dose Cytokines in Rheumatoid Arthritis, Three Birds with One Stone as the Rationale of the 2LARTHInternational journal of molecular sciences · 2021Review
- Low dose IL-2 suppress osteoclastogenesis in collagen-induced arthritis via JNK dependent pathway.Immunity, inflammation and disease · 2020Article
Corrections and comments
- Erratum issuedCorrigendum.2022
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRheumatoid arthritis (RA) is one of the most common chronic immune joint diseases, mainly involving blood vessels and small joints. The complex pathogenesis of RA greatly increases the difficulty of treatment. At present, the common hormone and immunosuppressive therapy are not effective, while low-dose interleukin-2 (IL-2) recently has been found to possess some advantages for immunotherapy. However, its related signal pathway remains to be elucidated.
methodsWe fabricated the model of arthritis in mice, and then low-dose IL-2 was injected at a fixed time point to observe the changes of related vascular and organ pathology, inflammatory factors, and signal pathway proteins, which were verified by statistical analysis.
resultsLow dose IL-2 can reduce the severity of vascular and bone lesions in collagen-induced arthritis immune model, and inhibit osteoclast formation in vitro by phosphorylation of nuclear factor-κB (NF-κB), which inhibits the receptor activator of NF-κB ligand effect through c-Jun N-terminal kinase (JNK) pathway, and its immunotherapeutic effect depends on the activation of JNK.
conclusionIt is the first time for us to prove that low dose IL-2 can inhibit osteoclast formation in collagen-induced arthritis through the JNK dependent pathway, which will provide the angle and theoretical basis for future immunotherapy of IL-2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.